NCT04516070 2026-03-05
Stereotactic Radiosurgery for the Treatment of Patients With Small Cell Lung Cancer Brain Metastasis
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
25 trialsNCT03223155 2026-03-04
COSINR
University of Chicago
Phase 1 Active not recruiting
NCT03830918 2026-02-12
Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy
Jonsson Comprehensive Cancer Center
Phase 1/2 Active not recruiting
NCT05616624 2026-02-04
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers
Washington University School of Medicine
Phase 1/2 Active not recruiting
NCT03923270 2026-01-08
Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Active not recruiting
NCT03728361 2025-12-18
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT04701307 2025-12-15
Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04010357 2025-12-02
Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC
Case Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT03672773 2025-11-10
TRIO-US L-07
Jonsson Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT04397003 2025-10-22
Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer
Washington University School of Medicine
Phase 2 Active not recruiting
NCT04472949 2025-10-01
Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).
Swiss Cancer Institute
Phase 2 Active not recruiting
NCT04986670 2025-09-30
NutriCare Plus a Medically Tailored Meal Intervention Among Patients With Lung Cancer
Tufts University
Phase NA Active not recruiting
NCT05796089 2025-08-26
CHEST RT
Trans Tasman Radiation Oncology Group
Phase 2 Active not recruiting
NCT07091305 2025-07-29
A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy
Shanghai Chest Hospital
Phase 2 Active not recruiting
NCT03670056 2025-07-20
Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based Chemotherapy
Yale University
Phase 2 Active not recruiting
NCT06227546 2025-07-08
MGC018-SCLC
Georgetown University
Phase 2 Active not recruiting
NCT03583528 2025-06-13
DOTATOC PET/CT for Imaging NET Patients
British Columbia Cancer Agency
Active not recruiting
NCT06748495 2025-02-27
Real-world First-line Serplulimab-based Immunochemotherapy for Extensive-stage Small Cell Lung Cancer
Hunan Cancer Hospital
Active not recruiting
NCT04165330 2025-02-24
Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors
Sarcoma Oncology Research Center, LLC
Phase 1/2 Active not recruiting
NCT03391362 2024-10-23
Stereotactic Radiation in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases
Dana-Farber Cancer Institute
Phase NA Active not recruiting
NCT06558903 2024-08-19
HYPE
University Hospital, Brest
Active not recruiting
NCT03540420 2024-07-15
ACHILES
Norwegian University of Science and Technology
Phase 2 Active not recruiting
NCT04562337 2024-07-03
SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in ES-SCLC
Shandong Cancer Hospital and Institute
Phase 2 Active not recruiting
NCT06483919 2024-07-03
The Predictive Value of Proteome Profiling for Brain Metastasis in Limited-Stage Small-Cell Lung Cancer
Shandong Cancer Hospital and Institute
Active not recruiting
NCT04487756 2024-04-03
VENEZO-LUNG
Instituto Oncológico Dr Rosell
Phase 1/2 Active not recruiting